Stocks in play: Medicenna Therapeutics Corp.
Today announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors. Medicenna Therapeutics Corp. shares T.MDNA are trading unchanged at $1.13.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.